Kestra Medical Technologies (NASDAQ:KMTS) Price Target Cut to $17.00 by Analysts at The Goldman Sachs Group

Key Points

• Goldman Sachs cut its price target on Kestra Medical Technologies from $22 to $17 and maintained a "neutral" rating, implying roughly an 11.9% downside from the current share price.
• Analyst opinions are mixed — three Buy, one Hold and one Sell — with a consensus target of $27.40, reflecting wide valuation disagreement among brokers.
• KMTS reported Q results showing EPS of $(0.61) (missing estimates by $0.01) and revenue up 62.7% year-over-year, yet the company remains unprofitable (negative net margin ~171.9% and ROE -65.5%); the stock traded around $19.30 on the report.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) had its target price lowered by equities researchers at The Goldman Sachs Group from $22.00 to $17.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. The Goldman Sachs Group's price target would indicate a potential downside of 11.89% from the company's current price.

A number of other research firms also recently commented on KMTS. Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a report on Friday, December 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Piper Sandler raised their price objective on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, December 12th. BTIG Research reaffirmed a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday. Finally, Wells Fargo & Company raised their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an "overweight" rating in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $27.40.

Kestra Medical Technologies Trading Down 1.7%

KMTS stock traded down $0.33 during midday trading on Thursday, reaching $19.30. The stock had a trading volume of 120,238 shares, compared to its average volume of 348,342. The business has a fifty day simple moving average of $22.91 and a two-hundred day simple moving average of $24.52. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.13 billion and a price-to-earnings ratio of -4.91. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.Kestra Medical Technologies's revenue for the quarter was up 62.7% compared to the same quarter last year.

Insider Buying and Selling

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total transaction of $304,050.00. Following the completion of the transaction, the insider owned 364,786 shares in the company, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 in the last ninety days. Corporate insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies in the first quarter valued at $11,036,000. Woodline Partners LP acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth about $2,510,000. Jane Street Group LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth about $756,000. Geode Capital Management LLC increased its stake in shares of Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company's stock worth $5,395,000 after purchasing an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Kestra Medical Technologies during the 2nd quarter worth about $256,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.